Regen BioPharma, Inc. (RGBP) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in La Mesa, CA, United States. The current CEO is David Raymond Koos.
RGBP has IPO date of 2014-10-06, 1 full-time employees, listed on the Other OTC, a market capitalization of $18.93K.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
